A series of monthly, online talks, aimed at discussing clinically-relevant updates and new approaches in Neuro-Oncology
About this Event

Horizons in Neuro-oncology is a series of talks and events to encourage collaboration and to increase the impact of research in neuro-oncology. The focus is on clinically applicable, or near-clinic, technologies and treatments that might improve patient outcomes, and in developing, supporting and implementing new treatments.

Although it is aimed at a clinical audience, it is open to all - health care professionals, students, researchers, charities, support groups, patients, carers and others.

Each session is typically 60 mins long, with a 40 - 45 minute talk, and then 15 min questions. All sessions are free to join and will be hosted online via Zoom. You are required to pre-register for each meeting in order to get the link. Recorded sessions will be made available afterwards on YouTube.

This month we are pleased to hear from Dr Nader Sanai M.D.

Nader Sanai, MD is the J.N. Harber Professor of Neurological Surgery at the Barrow Neurological Institute. Dr. Sanai was elected to the American Academy of Neurological Surgeons in 2016.

In 2018, he founded and now directs the Ivy Brain Tumor Center, a not for-profit drug development program specializing in Phase 0 trials and other pharmacokinetic- and pharmacodynamic-driven studies for brain tumors. Dr. Sanai has authored more than 200 peer reviewed publications and delivered over 100 national and international lectures in neuro-oncology.

In particular, he has pioneered the developed of Window trials in neuro-oncology. These provide a way of studying the effects of drugs in patients with brain tumours, and have led to the development of the phase 3 trial of Niraparib in patients with newly diagnosed GBM.